Patient Reported Outcomes and Measures in Children with Rhabdomyosarcoma

In addition to optimising survival of children with rhabdomyosarcoma (RMS), more attention is now focused on improving their quality of life (QOL) and reducing symptoms during treatment, palliative care or into long-term survivorship. QOL and ongoing symptoms related to the disease and its treatment...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2023-01, Vol.15 (2), p.420
Main Authors: van Gorp, Marloes, Grootenhuis, Martha A, Darlington, Anne-Sophie, Wakeling, Sara, Jenney, Meriel, Merks, Johannes H M, Hjalgrim, Lisa Lyngsie, Adams, Madeleine
Format: Article
Language:English
Subjects:
Cancer therapies
Children
Clinical medicine
Clinical trials
Medical treatment
Palliative care
Patients
Pediatrics
Quality of life
Radiation therapy
Rhabdomyosarcoma
Sarcoma
Self image
Surgery
Survival
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In addition to optimising survival of children with rhabdomyosarcoma (RMS), more attention is now focused on improving their quality of life (QOL) and reducing symptoms during treatment, palliative care or into long-term survivorship. QOL and ongoing symptoms related to the disease and its treatment are outcomes that should ideally be patient-reported (patient-reported outcomes, PROs) and can be assessed using patient-reported outcome measures (PROMS). This commentary aims to encourage PRO and PROM use in RMS by informing professionals in the field of available PROMs for utilisation in paediatric RMS and provide considerations for future use in research and clinical practice. Despite the importance of using PROMs in research and practice, PROMs have been reported scarcely in paediatric RMS literature so far. Available literature suggests lower QOL of children with RMS compared to general populations and occurrence of disease-specific symptoms, but a lack of an RMS-specific PROM. Ongoing developments in the field include the development of PROMs targeted at children with RMS specifically and expansion of PROM evaluation within clinical trials.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers15020420